2021 SPEAKERS

 

Dennis Akkaya, CCO, myTomorrows

Dennis Akkaya | CCO | myTomorrows » speaking at Orphan Drug Congress

Yazi Al'joboori, Business Lead, University College London

Yazi Al'joboori | Business Lead | University College London » speaking at Orphan Drug Congress

Luke Allen, Clinical Scientist, Cambridge Cognition Ltd

Luke Allen | Clinical Scientist | Cambridge Cognition Ltd » speaking at Orphan Drug Congress

Steven M Altschuler, Managing Director, Ziff Capital Partners

Steven M Altschuler | Managing Director | Ziff Capital Partners » speaking at Orphan Drug Congress

Diego Ardigo, Head of R&D, Global Rare Diseases, Chiesi Farmaceutici SpA

Diego Ardigo | Head of R&D, Global Rare Diseases | Chiesi Farmaceutici SpA » speaking at Orphan Drug Congress

Francis Arickx, Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy, Riziv-Inami

Francis Arickx | Head Of The Directorate Reimbursement Of Medicines And Pharmaceutical Policy | Riziv-Inami » speaking at Orphan Drug Congress

Bernard Avouac, Managing Director, Consultant, Market Access And Reimbursement, C2A

Oswald Bentinck, Vice President, Head Of Market Access EMEA, Novartis Gene Therapies

Oswald Bentinck | Vice President, Head Of Market Access EMEA | Novartis Gene Therapies » speaking at Orphan Drug Congress

Axel Boehnke, Director Market Access EU North, PTC Therapeutics

Axel Boehnke | Director Market Access EU North | PTC Therapeutics » speaking at Orphan Drug Congress

Thomas Bols, Head of Government Affairs and Public Policy, EMEA & APAC, PTC Therapeutics

Thomas Bols | Head of Government Affairs and Public Policy, EMEA & APAC | PTC Therapeutics » speaking at Orphan Drug Congress

Matt Bolz-Johnson, ERN & Healthcare Advisor, EURORDIS

Matt Bolz-Johnson | ERN & Healthcare Advisor | EURORDIS » speaking at Orphan Drug Congress

Simone Boselli, Director, Public Affairs, EURORDIS

Simone Boselli | Director, Public Affairs | EURORDIS » speaking at Orphan Drug Congress

Anna Bucsics, Project Advisor, Mechanism of Coordinated Access to orphan medicinal products (MoCA)

Anna Bucsics | Project Advisor | Mechanism of Coordinated Access to orphan medicinal products (MoCA) » speaking at Orphan Drug Congress

Vittoria Carraro, Associate Director Government Affairs, EUCOPE, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Vittoria Carraro | Associate Director Government Affairs, EUCOPE | European Confederation of Pharmaceutical Entrepreneurs (Belgium) » speaking at Orphan Drug Congress

Manuel Carrondo, Director, iBET: Instituto de Biologia Experimental e Tecnológica

Manuel Carrondo | Director | iBET: Instituto de Biologia Experimental e Tecnológica » speaking at Orphan Drug Congress

Anne-Sophie Chalandon, Head Of Rare Diseases, Public Affairs And Patient Advocacy, Sanofi Genzyme

Anne-Sophie Chalandon | Head Of Rare Diseases, Public Affairs And Patient Advocacy | Sanofi Genzyme » speaking at Orphan Drug Congress

Charlotte Chanson, Director Global Diagnostics, Orchard Therapeutics

Charlotte Chanson | Director Global Diagnostics | Orchard Therapeutics » speaking at Orphan Drug Congress

Angela Columbano, Head Of Business Development And Partnership, Genethon

Angela Columbano | Head Of Business Development And Partnership | Genethon » speaking at Orphan Drug Congress

Jean-Philippe Combal, Co-Founder And Chief Executive Officer, Vivet Therapeutics

Jean-Philippe Combal | Co-Founder And Chief Executive Officer | Vivet Therapeutics » speaking at Orphan Drug Congress

Rich Cooper, Chief Commercial Officer, Cambridge Cognition Ltd

Rich Cooper | Chief Commercial Officer | Cambridge Cognition Ltd » speaking at Orphan Drug Congress

Francesca Cormack, Director, Research And Innovation, Cambridge Cognition Ltd

Francesca Cormack | Director, Research And Innovation | Cambridge Cognition Ltd » speaking at Orphan Drug Congress

Avril Daly, Vice Chair, EURORDIS, Chief Executive Officer, Retina International

Avril Daly | Vice Chair, EURORDIS, Chief Executive Officer | Retina International » speaking at Orphan Drug Congress

Carla Deakin, Programme Director - Commercial And Managed Access, NICE

Carla Deakin | Programme Director - Commercial And Managed Access | NICE » speaking at Orphan Drug Congress

Pierre Delsaux, Directorate-General for Health and Food Safety, European Commission

Lauren DeRienzo, Med Affairs Lead, Xenon Pharmaceuticals

Lauren DeRienzo | Med Affairs Lead | Xenon Pharmaceuticals » speaking at Orphan Drug Congress

Toon Digneffe, Head of Public Affairs And Public Policy, Takeda

Toon Digneffe | Head of Public Affairs And Public Policy | Takeda » speaking at Orphan Drug Congress

Martin Dorazil, Deputy Head of Unit, European Reference Networks and Digital Health, European Commission

Martin Dorazil | Deputy Head of Unit, European Reference Networks and Digital Health | European Commission » speaking at Orphan Drug Congress

James Doyle, CEO, Modelis Inc

James Doyle | CEO | Modelis Inc » speaking at Orphan Drug Congress

Simon Eade, Global Commercial Strategy Lead Pulmonary Hypertension, Janssen

Karen Facey, Senior Research Fellow, University of Edinburgh

Karen Facey | Senior Research Fellow | University of Edinburgh » speaking at Orphan Drug Congress

Geoff Fatzinger, Mging Director, CCPS UK, & Global VP of Quality, Regulatory & Strategic Services, Caligor Coghlan Pharma Services

Geoff Fatzinger | Mging Director, CCPS UK, & Global VP of Quality, Regulatory & Strategic Services | Caligor Coghlan Pharma Services » speaking at Orphan Drug Congress

Alessandra Ferlini, Director of the Medical Genetics Section & Unit, University of Ferrara

Alessandra Ferlini | Director of the Medical Genetics Section & Unit | University of Ferrara » speaking at Orphan Drug Congress

Pedro Franco, Director of Europe for Global Regulatory & Scientific Policy (GRASP), Merck Serono

Pedro Franco | Director of Europe for Global Regulatory & Scientific Policy (GRASP) | Merck Serono » speaking at Orphan Drug Congress

Karl Freemyer, Head of Business Development, FIECON

Karl Freemyer | Head of Business Development | FIECON » speaking at Orphan Drug Congress

Michela Gabaldo, Head Of Alliance Management, Fondazione Telethon

Michela Gabaldo | Head Of Alliance Management | Fondazione Telethon » speaking at Orphan Drug Congress

Juan Garcia, Managing Partner, Biotechnology Business Institute

Juan Garcia | Managing Partner | Biotechnology Business Institute » speaking at Orphan Drug Congress

Nicolas Garnier, Director of Patient Advocacy, Global Product Development, Pfizer

Nicolas Garnier | Director of Patient Advocacy, Global Product Development | Pfizer » speaking at Orphan Drug Congress

Laura Germine, Director, Laboratory for Brain and Cognitive Health Technology, Harvard Medical School

Laura Germine | Director, Laboratory for Brain and Cognitive Health Technology | Harvard Medical School » speaking at Orphan Drug Congress

Josie Godfrey, Co-Founder and CEO, Realise Advocacy

Josie Godfrey | Co-Founder and CEO | Realise Advocacy » speaking at Orphan Drug Congress

Wim Goettsch, Special Hta-Advisor, Zorginstituut

Wim Goettsch | Special Hta-Advisor | Zorginstituut » speaking at Orphan Drug Congress

Jose F. Gomez, SVP, Global Market Access & Value, AVROBIO

Jose F. Gomez | SVP, Global Market Access & Value | AVROBIO » speaking at Orphan Drug Congress

Bernard Grimm, Director, Healthcare Technology, EuropaBio

Bernard Grimm | Director, Healthcare Technology | EuropaBio » speaking at Orphan Drug Congress

Marcus Guardian, Chief Operating Officer, EUnetHTA

Marcus Guardian | Chief Operating Officer | EUnetHTA » speaking at Orphan Drug Congress

Virginia Haurigot, Ocular Research Lead, Spark Therapeutics

Virginia Haurigot | Ocular Research Lead | Spark Therapeutics » speaking at Orphan Drug Congress

Niklas Hedberg, Head Of Pharmacy, Tandvards och Lakemedelsformansverket

Niklas Hedberg | Head Of Pharmacy | Tandvards och Lakemedelsformansverket » speaking at Orphan Drug Congress

Carlo Incerti, Operating Partner, Forbion

Carlo Incerti | Operating Partner | Forbion » speaking at Orphan Drug Congress

Daria Julkowska, Assistant Director, Thematic Institute of Genetics, Genomics & Bioinformatics, Inserm

Daria Julkowska | Assistant Director, Thematic Institute of Genetics, Genomics & Bioinformatics | Inserm » speaking at Orphan Drug Congress

Robin Kenselaar, Senior Vice President And General Manager EMEA, Orchard Therapeutics

Robin Kenselaar | Senior Vice President And General Manager EMEA | Orchard Therapeutics » speaking at Orphan Drug Congress

Anis Ben Kheder, Global Patient Access Director, Immunology, Sobi (Swedish Orphan Biovitrum)

Anis Ben Kheder | Global Patient Access Director, Immunology | Sobi (Swedish Orphan Biovitrum) » speaking at Orphan Drug Congress

Akshay Kumar, Partner, Partners4Access

Akshay Kumar | Partner | Partners4Access » speaking at Orphan Drug Congress

Giancarlo La Marca, Head, Newborn Screening, Clinical Chemistry and Pharmacology Lab, University Of Florence And Meyer Children's Hospital

Giancarlo La Marca | Head, Newborn Screening, Clinical Chemistry and Pharmacology Lab | University Of Florence And Meyer Children's Hospital » speaking at Orphan Drug Congress

John Lagus, EVP, Business Development, Tanner Pharma Group

John Lagus | EVP, Business Development | Tanner Pharma Group » speaking at Orphan Drug Congress

Guillem Laporta, Principal, Ysios Capital

Guillem Laporta | Principal | Ysios Capital » speaking at Orphan Drug Congress

Yann Le Cam, Chief Executive Officer, EURORDIS

Yann Le Cam | Chief Executive Officer | EURORDIS » speaking at Orphan Drug Congress

Anne Lee, Chief Pharmacist and Lead Officer, Scottish Medicines Consortium

Esther Mahillo, Executive Director Operational Strategy, Precision for medicine

Esther Mahillo | Executive Director Operational Strategy | Precision for medicine » speaking at Orphan Drug Congress

Steve Maricich, Chief Medical Officer, Allievex Corporation

Marc Martinell, CEO, Minoryx Therapeutics

Marc Martinell | CEO | Minoryx Therapeutics » speaking at Orphan Drug Congress

Paolo Martini, Chief Scientific Officer, Rare Diseases, Moderna Therapeutics

Guillem Masferrer, Investment Director, Asabys Partners

Guillem Masferrer | Investment Director | Asabys Partners » speaking at Orphan Drug Congress

Samarendra Mohanty, Founder And President, NanoScope Technologies

Samarendra Mohanty | Founder And President | NanoScope Technologies » speaking at Orphan Drug Congress

Nathalie Moll, Director General, EFPIA

Nathalie Moll | Director General | EFPIA » speaking at Orphan Drug Congress

Marisol Montolio Del Olmo, Scientific Director, Duchenne Parent Project Spain

Marisol Montolio Del Olmo | Scientific Director | Duchenne Parent Project Spain » speaking at Orphan Drug Congress

Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine

Paolo Morgese | EU Director Market Access & Member Relations | Alliance for Regenerative Medicine » speaking at Orphan Drug Congress

Jonathan Morton, Agency lead, Comradis, Comradis

Jonathan Morton | Agency lead, Comradis | Comradis » speaking at Orphan Drug Congress

Arne Müller, AD & Senior Principal Data Scientist in Clinical Digital Endpoints, Novartis

Arne Müller | AD & Senior Principal Data Scientist in Clinical Digital Endpoints | Novartis » speaking at Orphan Drug Congress

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Alexander Natz | Secretary General | European Confederation of Pharmaceutical Entrepreneurs (Belgium) » speaking at Orphan Drug Congress

David Nestor, Head of Neuromuscular Disease, Europe, Canada and Partner Markets, Biogen

David Nestor | Head of Neuromuscular Disease, Europe, Canada and Partner Markets | Biogen » speaking at Orphan Drug Congress

Elena Nicod, Research Fellow, Bocconi University

Elena Nicod | Research Fellow | Bocconi University » speaking at Orphan Drug Congress

Brendon Noble, Chief Scientific Officer, UK Stem Cell Foundation

Brendon Noble | Chief Scientific Officer | UK Stem Cell Foundation » speaking at Orphan Drug Congress

Daniel O'Connor, Expert Medical Assessor in Licensing Division, Medicines and Healthcare products Regulatory Agency

Daniel O'Connor | Expert Medical Assessor in Licensing Division | Medicines and Healthcare products Regulatory Agency » speaking at Orphan Drug Congress

Raj Pallapothu, Managing Director, Bio 9 Ventures

Raj Pallapothu | Managing Director | Bio 9 Ventures » speaking at Orphan Drug Congress

Francis Pang, Global Head of Market Access, Orchard Therapeutics

Francis Pang | Global Head of Market Access | Orchard Therapeutics » speaking at Orphan Drug Congress

Samantha Parker, Chief Patient Access Officer, Lysogene

Samantha Parker | Chief Patient Access Officer | Lysogene » speaking at Orphan Drug Congress

Detlev Parow, Head Pharmaceutical Department, DAK-Gesundheit

Detlev Parow | Head Pharmaceutical Department | DAK-Gesundheit » speaking at Orphan Drug Congress

Vinciane Pirard, Senior Director Government Relations, Orchard Therapeutics

Vinciane Pirard | Senior Director Government Relations | Orchard Therapeutics » speaking at Orphan Drug Congress

Giles Platford, President, Europe & Canada, Takeda Pharmaceutical Company

Giles Platford | President, Europe & Canada | Takeda Pharmaceutical Company » speaking at Orphan Drug Congress

Emmanuelle Quilès, Worldwide Vice President, Janssen

Momir Radulovic, Executive Director, JAZMP

Momir Radulovic | Executive Director | JAZMP » speaking at Orphan Drug Congress

Frederic Revah, Chief Executive Officer, Genethon

Frederic Revah | Chief Executive Officer | Genethon » speaking at Orphan Drug Congress

Christopher M de M Rudolf, CEO, volv global

Christopher M de M Rudolf | CEO | volv global » speaking at Orphan Drug Congress

Maurizio Scarpa, Director, Coordinating Center For Rare Diseases, MetabERN

Maurizio Scarpa | Director, Coordinating Center For Rare Diseases | MetabERN » speaking at Orphan Drug Congress

Sophie Schmitz, Managing Partner, Partners4Access

Sophie Schmitz | Managing Partner | Partners4Access » speaking at Orphan Drug Congress

Martin Schuchardt, Director Pricing and Market Access, FIECON

Martin Schuchardt | Director Pricing and Market Access | FIECON » speaking at Orphan Drug Congress

Tamir Singer, Head of Commercial Development, NHS England

Tamir Singer | Head of Commercial Development | NHS England » speaking at Orphan Drug Congress

Siân Smethurst, Head of Global Clinical Operations, Biogen

Siân Smethurst | Head of Global Clinical Operations | Biogen » speaking at Orphan Drug Congress

Pietro Sternini, Market Access & Marketing Lead EMEA, Astellas Gene Therapies

Pietro Sternini | Market Access & Marketing Lead EMEA | Astellas Gene Therapies » speaking at Orphan Drug Congress

Magali Taiel, Medical Chief Officer, Gensight Biologics

Magali Taiel | Medical Chief Officer | Gensight Biologics » speaking at Orphan Drug Congress

Koen Torfs, VP Global Reimbursement & Real World Evidence, Janssen

Sheela Upadhyaya, Accelerated Access Collaborative Relationship & Delivery Lead & HST Specialist, National Institute for Health and Care Excellence

Sheela Upadhyaya | Accelerated Access Collaborative Relationship & Delivery Lead & HST Specialist | National Institute for Health and Care Excellence » speaking at Orphan Drug Congress

Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, R.I.Z.I.V. I.N.A.M.I. National Health Insurance Agency

Inneke Van De Vijver | Strategic Advisor - Reimbursement Pharmaceuticals | R.I.Z.I.V. I.N.A.M.I. National Health Insurance Agency » speaking at Orphan Drug Congress

Sander Van Deventer, Operating Partner, Forbion Capital Partners

Sander Van Deventer | Operating Partner | Forbion Capital Partners » speaking at Orphan Drug Congress

Dirk Vander Mijnsbrugge, Vice President and Medical Affairs Lead Rare Diseases International Developed Markets, Pfizer Manufacturing Belgium

Birgitte Volck, Non Executive Director, Soleno Therapeutics

Birgitte Volck | Non Executive Director | Soleno Therapeutics » speaking at Orphan Drug Congress

Neil Watson, Business Development Director, Clinigen Group

Neil Watson | Business Development Director | Clinigen Group » speaking at Orphan Drug Congress

Sarah Weckhuysen, Neurologist, University Of Antwerp

Sarah Weckhuysen | Neurologist | University Of Antwerp » speaking at Orphan Drug Congress

Richard White, Chief Operating Officer, Oxford PharmaGenesis Ltd

Richard White | Chief Operating Officer | Oxford PharmaGenesis Ltd » speaking at Orphan Drug Congress

Vanessa Wolfeler, Global Franchise Head, Rare Blood Disorders, Sanofi Genzyme

Vanessa Wolfeler | Global Franchise Head, Rare Blood Disorders | Sanofi Genzyme » speaking at Orphan Drug Congress

Durhane Wong-Rieger, President & CEO, Canadian Organization for Rare Disorders

Durhane Wong-Rieger | President & CEO | Canadian Organization for Rare Disorders » speaking at Orphan Drug Congress

Adam Zaeske, Head of Portfolio & Pipeline, Europe & Canada, Takeda

Adam Zaeske | Head of Portfolio & Pipeline, Europe & Canada | Takeda » speaking at Orphan Drug Congress

Martine Zimmermann, Global Head Of Regulatory Affairs, Alexion Pharmaceuticals

Martine Zimmermann | Global Head Of Regulatory Affairs | Alexion Pharmaceuticals » speaking at Orphan Drug Congress

World Orphan Drug Congress

 

The World Orphan Drug Congress provides you with a one stop progressive scientific and strategic solution to the orphan drugs industry.

 

 

Events


World Orphan Drug Congress

Rare Disease Day

 

 

Contact us


To sponsor or exhibit:
Michael Hodge

Michael.hodge@terrapinn.com


To speak:
Wing-Yun Cheung

wing-yun.cheung@terrapinn.com


Nadia Konneh

nadia.konneh@terrapinn.com